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Abstract
Background: The apparent high number of deaths in Argentina during the 2009 pandemic led to concern that the influenza
A H1N1pdm disease was different there. We report the characteristics and risk factors for influenza A H1N1pdm fatalities.
Methods: We identified laboratory-confirmed influenza A H1N1pdm fatalities occurring during June-July 2009. Physicians
abstracted data on age, sex, time of onset of illness, medical history, clinical presentation at admission, laboratory,
treatment, and outcomes using standardize questionnaires. We explored the characteristics of fatalities according to their
age and risk group.
Results: Of 332 influenza A H1N1pdm fatalities, 226 (68%) were among persons aged ,50 years. Acute respiratory failure
was the leading cause of death. Of all cases, 249 (75%) had at least one comorbidity as defined by Advisory Committee on
Immunization Practices. Obesity was reported in 32% with data and chronic pulmonary disease in 28%. Among the 40
deaths in children aged ,5 years, chronic pulmonary disease (42%) and neonatal pathologies (35%) were the most common
co-morbidities. Twenty (6%) fatalities were among pregnant or postpartum women of which only 47% had diagnosed co-
morbidities. Only 13% of patients received antiviral treatment within 48 hours of symptom onset. None of children aged ,5
years or the pregnant women received antivirals within 48 h of symptom onset. As the pandemic progressed, the time from
symptom-onset to medical care and to antiviral treatment decreased significantly among case-patients who subsequently
died (p,0.001).
Conclusion: Persons with co-morbidities, pregnant and who received antivirals late were over-represented among influenza
A H1N1pdm deaths in Argentina, though timeliness of antiviral treatment improved during the pandemic.
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Introduction
In April 2009, pandemic influenza H1N1 2009 (influenza A
H1N1pdm virus emerged in Mexico and the United States [1].
Argentina was one of the first countries to experience pandemic
H1N1 virus transmission during the usual influenza season [2],
[3]. The first influenza A H1N1pdm-confirmed case was identified
on April 28
th 2009. This and subsequent cases were among
travelers arriving from North America. The virus did not spread in
the community until mid-May. The first group affected was
school-aged children in Buenos Aires.
On June 15
th 2009, the first fatal influenza A H1N1pdm case in
Argentina was confirmed [4]. Ten days later, 22 additional
influenza A H1N1pdm fatalities were confirmed in the province of
Buenos Aires. During July (epidemiological weeks 26–30), the
number of laboratory-confirmed influenza A H1N1pdm cases rose
from 2,409 to 5,712 and the number of confirmed deaths from 55
to 337 which represented an increase in case-fatality proportion
among reported cases from 2.2% to 5.9%. This was the largest
number of influenza A H1N1pdm deaths reported from any
country at that time. Although the initial elevated mortality was
considered a surveillance artifact, concerns remained that
influenza A H1N1pdm disease evolution was somehow different
in Argentina. Public health officials were also concerned that
prevention and treatment measures might not have been
sufficiently targeted, given the limited size of local oseltamivir
stockpiles for presumptive treatment of case-patients.
On June 26
th 2009, the National Ministry of Health of
Argentina (NMHA) created the National Commission for the
Assessment of Influenza A (H1N1) to assess clinical aspects of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33670influenza A H1N1pdm illness among fatalities, adequacy and
timeliness of treatment, and possible risk factors for severe illness
[5]. In this report, we describe the features of 332 laboratory-
confirmed influenza A H1N1pdm fatalities with available clinical
data that occurred during June 15–July 31 2009, at the peak of
influenza A H1N1pdm transmission in Argentina.
Methods
In April 2009, the Government of Argentina activated the
national Emergency Situation Room (ESR). Each province
reported laboratory and epidemiological data on confirmed
influenza A H1N1pdm fatalities and hospitalizations through the
National Health Surveillance System and from laboratories
performing real-time reverse-transcription polymerase-chain-reac-
tion (rRT-PCR) for influenza A H1N1pdm through the
Laboratory Surveillance System [6], [7]. Public and private health
institutions were mandated to notify the ESR of hospitalized
influenza A H1N1pdm case-patients who subsequently died.
For this study, a confirmed fatal case was defined as a patient
who tested positive for influenza A H1N1pdm and who died in the
period June 15-July 31 2009 (i.e. the peak of the pandemic). To
identify cases, we searched a list of influenza A H1N1pdm
laboratory-confirmed fatalities reported to the ESR by private and
public institutions from the city of Buenos Aires and the seven
provinces with the highest number of reported confirmed cases
(i.e. Buenos Aires, Santa Fe, Co ´rdoba, Neuque ´n, Rı ´o Negro,
Tucuma ´n, and Entre Rı ´os).
Physicians abstracted data on age, sex, medical history,
comorbidities (i.e. chronic pulmonary, cardiovascular, renal,
hepatic, hematological, metabolic, neurologic, immunologic and
neonatal disorders), selected risk factors (e.g. obesity, defined as
BMI.30 or subjectively assessed; pregnancy, alcoholism, and
smoking), previous hospitalizations, signs and symptoms, clinical
Figure 1. Pandemic H1N1 (influenza A H1N1pdm) confirmed hospitalizations and deaths by week of symptom onset and case
fatality proportion among hospitalized cases, Argentina, May 3
rd 2009–August 29
th 2009.
doi:10.1371/journal.pone.0033670.g001
Table 1. Age and sex distribution of fatalities reported from June 15
th to July 31
st 2009, Argentina.
Fatalities reported
N=332 Fatalities reported (%) Population* (N) Population (%) No. fatalities reported per 100,000 pop
Age
0t o4 48 14 3,349,278 9 1.4
5t o1 8 45 14 9,442,608 26 0.5
19 to 49 134 40 15,241,760 42 0.9
50 to 64 75 23 4,638,864 13 1.6
65+ 30 9 3,587,620 10 0.8
Sex
Male 177 53 17,659,072 49 1.0
Female 155 47 18,601,058 51 0.8
*Argentina census data (INDEC. Censo Nacional de Poblacio ´n, Hogares y Viviendas 2001).
doi:10.1371/journal.pone.0033670.t001
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and intensive care, radiographic findings, use of oseltamivir, and
laboratory results using a standardized form. Nosocomial
influenza A H1N1pdm virus infection was defined as a patient
who developed respiratory symptoms .48 hours after admission
for a non-respiratory cause and who later tested positive for
influenza A H1N1pdm. Organ failures were defined according to
international definitions [8,9]. If a patient was mechanically
ventilated, but not admitted to intensive care unit (ICU) because of
space limitations, the case was still classified as an ICU patient. All
collected data were reviewed by physicians from the ESR and the
National Commission for the Assessment of Influenza A (H1N1) to
detect possible inconsistencies. Data was not captured if deaths
occurred outside the hospital, the medical records were unavail-
able, or occurred outside the study period.
Respiratory specimens were collected from suspected cases and
were tested for influenza A H1N1pdm by rRT-PCR assay initially
in Argentina’s National Reference Laboratory. As the pandemic
progressed, an additional 18 laboratories were trained to use this
technique and provided data for the study.
Differences in categorical variables among the three age groups
(i.e.,5, 5–49, and .50 years) were analyzed by X
2 tests and
Fisher’s exact test. Student t-tests and one-way analysis of variance
(ANOVA) were used to compare means and Wilcoxon Rank sum
test to compare medians.
Ethics statement
To maintain data confidentiality, unique identifiers on medical
records were coded. Institutional review board approval was not
required as the NMHA empowered the commission to confiden-
tially review medical records of influenza A H1N1pdm fatalities
through a ministerial resolution [5] during this public health
emergency.
Results
During 2009, 626 patients died with laboratory-confirmed
influenza A H1N1pdm infection in Argentina [10]. The
proportion of confirmed hospitalized case-patients who died
peaked during June (i.e. 48 [18%] of 272) (Figure 1). Of the 626
fatalities, 377 were reported during June 15-July 31 (the study
period). Forty-five were excluded because 37 were not confirmed
by RT-PCR and eight had incomplete medical charts.
The remaining 332 fatalities had a median age of 36 years
(IQR=13–53 years) and 177 (53%) were male. Children aged
,18 years accounted for 93 (28%) of fatalities, those aged ,5
years comprised 48 (52%), and infants aged less ,6 months
comprised 16 (33%). Although more fatalities were reported
among patients aged 19–49 years, laboratory-confirmed influenza
A H1N1pdm fatalities per 100,000 population were more
common among children aged ,5 years and persons aged 50–
64 years (Table 1).
Table 2. Selected symptoms and physical signs at time of admission by age group in influenza A H1N1pdm confirmed fatalities
(excluding patients with influenza A H1N1pdm nosocomial infections unless otherwise reported), Argentina, June 15
th–July 31
st,
2009.
Age groups (years)
,5
N=48
5–49
N=179
50+
N=105
All ages
N=332
N/total num of charts with data (%)*
influenza A H1N1pdm nosocomial infections 7/48 (13) 17/179 (9) 6/105 (6) 30/332 (8)
Symptoms reported at presentation
Fever 25/30 (83) 118/132 (89) 59/76 (78) 202/238 (85)
Dyspnea 34/38 (89) 133/141 (94) 87/91 (96) 254/270 (94)
Cough 14/19 (75) 124/133 (93) 84/88 (96) 222/240 (93)
Gastrointestinal 4/21 (19) 34/96 (35) 13/66 (20) 51/183 (28)
Headache 1/4 (25) 28/48 (58) 15/39 (38) 44/91 (48)
Sore throat 1/6 (17) 18/55 (33) 10/37 (27) 29/98 (30)
Physical signs at admission
Temperature{ 36.5 (36, 37.4) 38 (36.9, 38.4) 37.2 (36.5, 38.3) 37.5 (36.5, 38.2)
Temperature.386C 5/32 (16) 68/135 (50) 36/86 (42) 109/253 (43)
Respiration rate{ 51 (40, 64) 30 (25, 40) 28 (24, 36) 32 (25, 40)
Elevated respiration rate# 24/30 (80) 90/120 (75) 50/75 (67) 164/225 (73)
Heart Rate{ 150 (130, 180) 112 (100, 120) 100 (82, 120) 110 (90, 128)
Elevated heart rate1 31/37 (84) 113/148 (76) 47/92 (51) 191/277 (69)
Systolic Blood Pressure{ 89 (79, 97) 110 (100, 130) 120 (100, 139.5) 110 (97, 130)
Low Systolic Blood Pressure" 6/13 (46) 16/138 (12) 11/92 (12) 33/243 (14)
Crackles 19/30 (63) 121/132 (92) 70/80 (88) 210/242 (87)
Wheezing 17/27 (63) 39/88 (44) 40/64 (63) 96/179 (54)
*Unless otherwise stated.
{Median (IQR).
#Elevated respiration rate was defined as more than 40 breaths per minute for patients less than 5 years old and 25 breaths per minute for patients 5+ years old.
1Elevated resting heart rate was defined as more than 120 beats per minute for patients less than 5 years old and 100 beats per minute for patients 5+ years old.
"Low systolic tension was defined as ,90 mmHg.
doi:10.1371/journal.pone.0033670.t002
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but rather acquired nosocomial influenza A H1N1pdm infections.
Excluding these cases, the most common symptoms at admission
were dyspnea (94%), cough (93%), and history of fever (85%).
During admission, most patients had elevated respiration rates
(73%) and heart rates (69%). On auscultation, crackles were more
common among fatalities aged $5 years compared to fatalities ,5
years (89% vs. 63%, p,0.01). Anemia was present in 54% of
patients, and more common among those aged ,5 years (67%,
p,0.01) (Table 2). Of 134 fatalities with available data, 110 (82%)
presented with lymphopenia. Of 159 fatalities with available data,
65 (41%) had thrombocytopenia. Elevated urea was more
Table 3. Selected hematology at time of admission by age group in influenza A H1N1pdm confirmed fatalities (excluding patients
with influenza A H1N1pdm nosocomial infections unless otherwise reported), Argentina, June 15–July 31, 2009.
Hematology
Leukopenia
(,4,500 cells/ml)
8/31 (26) 38/124 (31) 20/85 (24) 66/240 (28)
Leukocytosis
(.11,000 cells/ml)
13/31 (42) 25/124 (20) 30/85 (35) 68/240 (28)
Lymphopenia** 15/21 (71) 56/71 (79) 38/41 (93) 109/133 (82)
Anemia{{ 28/41 (68) 66/162 (41) 44/99 (44) 138/302 (54)
Thrombocytopenia
(,150,000 cells/ml)
6/25 (24) 40/81 (49) 19/53 (36) 65/159 (41)
Chemistry
Elevated Urea
(.42 mg %)
9/19 (47) 40/99 (40) 51/70 (73) 100/188 (53)
Elevated AST (.80 UI/ml) 7/13 (54) 26/55 (47) 16/35 (46) 49/103 (48)
Elevated ALT (.80 UI/ml) 5/13(38) 14/56 (25) 8/31 (26) 27/100 (27)
Acid-base
O2 Saturation ,96% 19/32 (59) 125/146 (86) 78/92 (85) 222/270 (82)
pH,7.36 15/20 (75) 41/102 (40) 40/77 (52) 96/199 (48)
Elevated pCO2
(.44 mmHg)
10/19 (53) 18/101 (18) 22/77 (29) 50/197 (25)
Acidosis or
Hypoxemia11
23/33 (70) 132/147 (90) 86/94 (92) 241/274 (88)
**Lymphopenia was defined as ,3000 cells/ml for patients under 5 years old, ,2000 cells/ml for patients 5-12 years old and ,1,500 cells/ml for patients over 12 years
old.
{{Anemia was defined as less than 11 g/dl of hemoglobin (Hb) for patients less than 5 years old and for pregnant women (.15 years old), less than 11.5 g/dl Hb for
patients 5–12 years old, less than 12 g/dl Hb for patients 12–15 years old and for non-pregnant women (.15 years old), and less than 13 g/dl Hb for men 15 years and
older.
11‘‘Acidosis or hypoxemia’’ is defined as pH under 7.36 or oxygen saturation less than 96%.
doi:10.1371/journal.pone.0033670.t003
Table 4. Selected X-ray patterns at time of admission by age group in influenza A H1N1pdm confirmed fatalities (excluding
patients with influenza A H1N1pdm nosocomial infections unless otherwise reported), Argentina, June 15
th–July 31
st, 2009.
X-Rays patterns at admission
Consolidation only 14/26 (54) 37/93 (40) 20/57 (35) 71/176 (40)
Bilateral 12/14 (86) 26/36 (72) 7/20 (35) 45/70 (65)
Interstitial only 8/26 (31) 29/93 (31) 24/57 (42) 61/176 (35)
Bilateral 8/8 (100) 28/29 (97) 23/24 (96) 59/61 (97)
Consolidation + Interstitial 3/26 (12) 23/93 (25) 11/57 (19) 37/176 (21)
Bilateral 3/3(100) 21/23 (91) 10/11 (91) 34/37 (92)
Primary Diagnosis at admission (includes patients that developed influenza A H1N1pdm nosocomial infections)
Pneumonia 26/48 (54) 133/179 (74) 78/105 (74) 237/332 (71)
Other respiratory diagnosis"" 16/48 (33) 28/179 (16) 21/105 (20) 65/332 (20)
No record of any respiratory diagnosis *** 6/48 (10) 18/179 (13) 6/105 (6) 30/332 (9)
""COPD, Asthma, atelectasis, tuberculosis, respiratory failure.
***Fever syndrome, septic shock, leukemia, gastrointestinal problems, pregnancy, HIV/AIDS.
doi:10.1371/journal.pone.0033670.t004
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groups (p,0.001). Eighty-two percent of patients had oxygen
saturation ,96%) which was more common among patients $5
years (p,0.01); while acidosis (pH,7.36) and elevated pCO2
(.44 mmHg) were more common among patients ,5 years
(p,0.01) (Table 3).
Among 176 patients with admission radiographs, (79%) had
bilateral chest infiltrates, 71 (40%) had consolidation, 61 (35%)
had interstitial pattern, 37 (21%) had both, and six (3%) had other
findings (Table 4). For 236 (71%) of the 332 patients (including
those with nosocomial infections), the primary hospital admission
diagnosis was pneumonia. Pneumonia, however, only accounted
for 54% of the primary diagnoses among children aged ,5 years,
with other respiratory illnesses accounting for over one third of the
admission diagnosis among this age group.
Of 304 patients admitted for influenza A H1N1pdm-associated
illness (excluding nosocomial infections), the median time from
symptom onset to admission was five days (IQR, 3–7 days). Most
patients (299 [95%] of 315) needed ICU admission and, 292 were
mechanically ventilated for a median of six days (IQR, 2–12 days).
Among the 252 patients with available information on the start
date of their mechanical ventilation, 207 (82%) were mechanically
ventilated within the first 24 hours of admission to intensive care
(Table 5).
The most frequent organ failure was respiratory failure (97%).
Additionally, 85% of the patients met the criteria for acute
respiratory distress syndrome (ARDS) during their hospitaliza-
tion. These patients had hypoxemia [median Pa/FiO2 87 (IQR:
60–129)], hypercapnia [median PaCO2 54 (IQR: 43–72), and
acidosis [median pH 7.24 (IQR: 7.10–7.33) requiring elevated
concentration of oxygen (FiO2 100% in 72% of cases), maximal
high positive end expiratory pressure [median 15 (IQR: 10–18)]
and use of ventilation in prone position or alveolar recruitment
maneuvers in 41% of patients. Hemodynamic failure requiring
vasoactive drugs occurred in 54% of patients. Renal failure was
present in 134 (43%) of the 312 patients with available data and
29% of these required dialysis. Of the 134 patients with renal
failure, 31 (23%) had previous chronic renal failure of which eight
[6%] were on chronic hemodialysis. Six (13%) of 47 children
aged ,5 years with available data developed renal failure
compared to 128 (48%) of 265 persons aged $5 years
(p,0.0001).Hematologic failure was diagnosed in 44%, hepatic
failure in 5% and multiorgan failure in 71% of influenza A
H1N1pdm fatalities.
Of all 332 patients, 290 (87%) received antiviral treatment;
183 (76%) #2 days of admission but only 33 (13%) of 253 with
information on timing of administration received antivirals
#48 hours of symptom onset. None of the 48 fatalities aged
,5 years received antivirals #48 hours of symptom onset;
20% of these children received antivirals #48 hours of a
doctor’s visit, and only 55% received antivirals #48 hours of
hospitalization compared to at least 78% in older age groups
(Table 5).
As the pandemic progressed, the mean time from symptom
onset to first doctor visit and symptom onset to hospitalization
among fatalities decreased (p,0.001). Similarly, the mean time
from symptom onset to antiviral treatment decreased from 19 days
during epidemiologic week 22 to four days during week 28
(p,0.001). The time from the first doctor visit to antiviral
treatment also decreased as the pandemic progressed (p,0.001)
while the time from hospitalization to antiviral treatment
remained brief (Figure 2A–E).
At least one comorbidity [11] was reported in 75% of cases with
such information in their charts. The most common comorbidities
were chronic pulmonary disease (including asthma) in 28%,
metabolic disorder (including diabetes) in 25%, and immunosup-
Table 5. Treatment and Clinical course of 332 influenza A H1N1pdm-confirmed fatalities, June 15
th–July 31
st, 2009.
,5 years 5–49 years .50 years Total
N=48 N=179 N=105 N=332
Antiviral use (ATV) N (%) total
Received ATV treatment 40/48 (83) 156/179 (87) 94/105 (90) 290/332 (87)
,48 hr after onset (early treatment) 0/36 (0) 23/139 (17) 12/79 (15) 33/253 (13)
,48 hr after first doctor visit 6/30 (20) 56/112 (50) 43/68 (63) 105/210 (50)
,48 hr after admission 18/33 (55) 103/129 (80) 62/79 (78) 183/241 (76)
Intensive care
ICU admission 46/47 (98) 162/170 (95) 91/98 (93) 299/315 (95)
Mechanical ventilation (MV) 47/47 (100) 160/174 (92) 85/99 (86) 292/320 (91)**
Median No. Days: ICU to MV (IQR) 0 (0–1)/38 0 (0–0)/140 0 (0–0)/73 0 (0–0)/233
Median No. Days on MV (IQR) 7 (4–13)/41 6 (2–12)/152 5 (2–11)/81 6 (2–12)/252
Timelines Median Days (IQR)/N***
Onset—First doctor visit 1 (0–3)/31 2 (0–4)/116 3 (1–5)/75 2 (0–4)/222
First doctor visit—ATV treatment 6 (3–10)/29 2 (0–5)/103 1 (0–5)/64 2 (0–5)/196
Onset—Hospitalization 6 (2–9)/27 4 (3–6)/125 5 (3–7)/79 5 (3–7)/231
Hospitalization—ATV treatment 1 (0–4)/27 0 (0–2)/118 0 (0–1)/73 0 (0–2)/218
Hospitalization—ICU 0 (0–2.5)/32 1 (0–2)/127 0 (0–1)/75 0 (0–1)/234
Onset—Death 15 (8.5–22)/32 12 (7–20.5)/140 13 (7–20)/87 13 (7–20)/259
**eleven case-patients were ventilated outside of the ICU because of space-limitations.
***excluding influenza A H1N1pdm nosocomial infections.
doi:10.1371/journal.pone.0033670.t005
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chronic pulmonary disease (42%) was also the most common
comorbidity followed by neonatal pathologies (i.e. genetic
disorders, congenital malformations, and preterm births) (35%)
and neurologic disease (19%) (Table 6). The prevalence of asthma
was low among fatalities (6%). In contrast, 4% of patients were
HIV positive, a proportion higher than the 0.4% country
prevalence [12]. Similarly, 32% of fatalities were obese, a
proportion higher than the 15% country prevalence [13].
We identified 16 pregnant women and four postpartum women
among fatalities. Four of the pregnant women were in their second
trimester while 11 were in their third trimester. Eight delivered by
caesarean section after being admitted to the ICU, two whom had
stillbirths. Pregnant women had significantly longer ICU stays
than non-pregnant women aged 15–44 years (11 vs. 4 days,
p=0.01). One pregnant and two postpartum women did not
receive any antiviral treatment during the course of their illness.
Among the 17 pregnant or postpartum women that received
Figure 2. Mean number of days from date of onset to date of first doctor visit (A), hospitalization (B), and antiviral treatment (C);
Mean number of days from first doctor visit (D) and hospitalization (E) to antiviral treatment among influenza A H1N1pdm
fatalities by epidemiological week of onset.
doi:10.1371/journal.pone.0033670.g002
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after illness onset but a median of seven days (IQR: 5–9 days) later.
Fifty percent received antivirals ,1 day after hospitalization
(Table 7).
Discussion
Most fatal cases presented to the hospital with acute severe
respiratory compromise or ARDS and required immediate
mechanical ventilation with respiratory failure as their main cause
of death. The median age of fatalities was consistent with those
found in other influenza A H1N1pdm studies [14], [15], [16],
[17], [18], [19]. Three-quarters of confirmed influenza A
H1N1pdm fatalities occurred among persons aged ,50 years,
however, the highest incidence of H1N1pdm fatalities occurred
among persons aged 50–65 years and children ,5 years (half of
them ,1 year).
Two-thirds of all cases had at least one comorbidity as defined
by ACIP [11]. In addition, healthy pregnant women were
disproportionately affected as has been found in other studies
[2], [20], [21], [22]. The unusually high proportion of decedents
who were obese in our case-series (i.e. 33%) is consistent with
studies [2] [23], [24] that suggest that obesity may be a risk factor
for severe influenza disease. Although our study did not determine
which fatalities had acquired immunodeficiency syndrome or were
on antiretroviral therapy, we found a higher prevalence of
influenza A H1N1pdm co-infection among HIV positive fatalities
when compared to the general population. Such data are
important because early reports suggested that HIV-infected
individuals might experience more severe complications from
influenza A H1N1pdm infection [20], [24], [25], [26], a finding
not confirmed in later studies [27], [28], [29].
Even though the government of Argentina recommended
oseltamivir treatment to high-risk persons [30], fewer than 15%
of fatalities received antiviral treatment during the recommended
48 hours after symptom onset and only half within 48 hours of a
physician visit. No children aged ,5 years received early
Table 6. Comorbidities* and underlying conditions among influenza A H1N1pdm confirmed fatalities by age groups, Argentina,
June 15
th–July 31
st, 2009.
Age groups ,5 5–49 50+ Total
N=48 N=179 N=105 N=332
Comorbidities* N (%) total
Chronic pulmonary disease{ 20/48 (42) 29/152 (19) 33/94 (35) 82/294 (28)
Asthma 0/41 (0) 11/142 (8) 5/89 (6) 16/272 (6)
Cardiovascular disease1 5/41 (12) 16/154 (10) 35/94 (37) 56/289 (19)
Renal disease 2/41 (5) 11/151 (7) 18/88 (21) 31/280 (11)
Hepatic disease 1/39 (3) 8/151 (5) 4/85 (5) 13/275 (5)
Hematological disease 3/38 (8) 22/148 (15) 8/88 (9) 33/274 (12)
Metabolic disorder" 3/42 (7) 34/156 (22) 35/91 (39) 72/289 (25)
Diabetes 0/40 (0) 22/150 (15) 22/87 (25) 44/277 (16)
Immunosuppression# 4/42 (10) 43/163 (26) 24/92 (26) 71/297 (24)
HIV/AIDS 0/38 (0) 10/155 (7) 1/85 (1) 11/278 (4)
Other comorbidities** 29/48 (60) 34/160 (21) 12/93 (13) 75/301 (25)
Neurologic disease{{ 9/48 (19) 33/160 (21) 12/93 (13) 54/301 (18)
Neonatal pathologies 17/48 (35) n/a n/a n/a
At least 1 comorbidity* 39/48 (81) 115/170 (68) 85/101 (84) 239/319 (75)
Underlying conditions
Obesity 0/40 (0) 54/154 (35) 34/82 (42) 88/276 (32)
Hypertension 1/40 (3) 28/153 (18) 58/94 (62) 87/287 (30)
Smoking11 n/a 35/171 (20) 29/103 (28) 64/321 (20)
Alcohol dependence n/a 9/145 (6) 15/86 (17) 24/269 (9)
Substance abuse n/a 6/142 (4) 2/81 (3) 8/261 (3)
Pregnancy/postpartum"" n/a 20/91 (22) 0/44 (0) 20/155 (13)
*Comorbidities as defined by the Advisory Committee on Immunization Practices
10.
{Including asthma.
1Excluding hypertension.
"Including diabetes.
#Persons who have immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus, HIV).
**Persons who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory
function or the handling of respiratory secretions or that can increase the risk for aspiration.
{{Including cerebrovascular disease, cerebral palsy, epilepsy, down syndrome, neurochronic disease.
11Does not include former and passive smokers.
""Women only.
n/a not applicable.
doi:10.1371/journal.pone.0033670.t006
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the physician visit. Although a previous case-series of 251 children
infected with influenza A H1N1pdm with 13 fatalities did not find
a difference between prompt consultation, ICU admission,
survival, and oseltamivir treatment [3], we recommend early
treatment based on the findings of larger case-series [31]. The
apparent reluctance to provide early antivirals to young children
may have been caused by the clinician’s lack of familiarity with the
use of oseltamivir and their concerns over potential adverse events
among very young children. Indeed, at the onset of the pandemic,
clinicians were required to provide antiviral treatment to children
aged ,1 under strict medical supervision and under hospital
supervision to children aged ,3 months [30].
The high proportion of pregnant or postpartum women in our
case-series of decedents is concordant with reports that identify
pregnancy as a risk factor for severe influenza illness and death
[21], [32], [32], [34], [35]. During the pandemic, pregnant
women were identified as high-risk and the government of
Argentina approved social distancing measures to protect them
such as strongly urging them to stay home from work with paid
leave. We observed that ,50% of pregnant women had
comorbidities, compared to 70% of influenza A H1N1pdm
infected non-pregnant women and 80% of pregnant women in
the U.S. [34]. In our study, these predominantly healthy pregnant
and postpartum women received antivirals a median of seven days
after symptom onset compared to five days among non-pregnant
women. Such finding that suggests that although antiviral
treatment #4 days after symptom onset was associated with
milder influenza A H1N1pdm disease [34], clinicians may have
been hesitant to use them possibly due to lack of familiarity with
the use of oseltamivir and their concerns over potential adverse
events among pregnant women and their unborn children.
Although other studies have shown a high frequency of dyspnea
in critically ill patients, our analyses demonstrates our case-patients
also frequently had tachypnea (73%), tachycardia (69%) and
acidosis and/or hypoxemia (88%) on admission. Gastrointestinal
symptoms were more frequently reported than in adults infected
with seasonal influenza but not as frequently as in other influenza
A H1N1pdm studies [14], [20], [21], [36]. Thrombocytopenia
upon admission was frequently observed among decedents, and
was more prevalent than previously reported among patients with
influenza A H1N1pdm infection [37], [38], [39].
During the pandemic, an insufficient number of ICU beds were
available for all patients. Critically ill patients occasionally received
mechanical ventilation outside the ICU, at the emergency
department or special facilities [40], [41]. In most patients, ARDS
with respiratory failure was the leading cause of death. This is in
contrast to ARDS caused by other etiologies where respiratory
failure accounts for ,20% of deaths [42], [43], [44]. This finding
has also been observed in other influenza A H1N1pdm studies [2],
[45], [46]. Acute renal failure requiring dialysis was observed
frequently among patients aged $5.
Our analysis indicates that time from symptom onset to clinic
visit and to hospitalization decreased as the pandemic progressed.
Time to antiviral treatment also decreased during the first two
weeks of the study. These data suggest that affected persons sought
care earlier and physicians used antivirals more rapidly as the
pandemic progressed and may explain why the case fatality
proportion of hospitalized patients decreased from a peak at the
beginning of the pandemic. The initial delay in health seeking may
have been caused by high risk persons that did not suspect that
they had influenza illness or that were not aware of the need to
seek care within 48 hours of symptom onset when antivirals are
most effective. The initial delay in treatment could have been
caused by unavailability of antivirals or by primary care physicians
unfamiliar with their use. In Argentina, only a small stockpile of
oseltamivir was available at the beginning of the pandemic which
was insufficient to treat all patients once influenza A H1N1pdm
spread throughout the country.
Our study has several limitations. Our case-series design did not
allow us to collect information from controls to further substantiate
whether potential risk factors were indeed associated with death
from H1N1pdm. The data obtained was limited to non-
standardized medical records and there was no opportunity to
confirm details with family members. Due to the limited
availability of laboratory testing during the study period, the
number of confirmed fatalities represented only about half of the
currently confirmed fatalities and may not be representative of
other fatalities during this period or of those who occurred at
home. Moreover, we only assessed hospitalized laboratory-
confirmed influenza A H1N1pdm fatalities for which we had
medical records, and these cases might have manifested differently
Table 7. Description of pregnant, postpartum and fertile age
women among influenza A H1N1pdm confirmed deceased
patients, Argentina, June 15
th–July 31
st, 2009.
Pregnant and
Postpartum (N=20)
Non-pregnant
(N=44)
Median age (range) 26.5 (19–41) 32.5 (16–44)
Postpartum at symptom onset 4n / a
Pregnant at symptom onset 16 n/a
Second trimester 4/15 n/a
Third trimester 11/15 n/a
Stillbirths 2/16 n/a
Delivered after ICU admittance 8/16 n/a
C-sections 13/14 n/a
Comorbidities
Chronic pulmonary disease 1/15 9/40 (23%)
Cardiovascular disease 1/17 3/39 (8%)
Renal disease 0/16 2/40 (5%)
Hepatic disease 0/16 4/39 (10%)
Hematological disease 3/18 3/37 (8%)
Metabolic disorder (diabetes) 3/18 16/39 (41%)
Immunosuppression 1/18 12/41 (29%)
Other condition 2/18 4/39 (10%)
At least 1 condition 9/19 29/42 (70%)
Obesity 2/16 16/38 (42%)
Hypertension 2/16 7/40 (18%)
Antiviral (ATV) treatment 17/20 39/44 (89%)
,48hrs from symptom onset 0/17 4/29 (14%)
Timelines: Median Days (IQR)
Onset—ATV treatment 7 (5–9) 5 (3–7)
First doctor visit—ATV treatment 4 (2.5–6) 1 (0–5)
Hospitalization—ATV treatment 1 (1–3) 0 (0–2)
Onset —Hospitalization 4 (2–6) 4 (2–5)
ICU— Death 11 (6–16) 4 (2–12)
Onset— Death 14 (13–17) 9 (5–18)
n/a not applicable.
doi:10.1371/journal.pone.0033670.t007
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Laboratory samples and tests did not follow a study protocol but
represented the choices made by clinicians during the manage-
ment of patients. Our study did not include autopsy data. Several
parameters that define risk factors and underlying conditions, such
as height and weight data, smoking history and alcohol
consumption, were not available for all case-patients. We were
unable to compare risk factors for death compared to severe
disease and the effect of antiviral treatment as we did not review
charts from surviving hospitalized patients.
After the study was conducted, Argentina has emphasized
protecting young children and pregnant women. The 2010
monovalent influenza A H1N1pdm influenza vaccination cam-
paign in Argentina aimed at a 95% coverage among pregnant
women and 85% coverage among children aged ,4 years [47].
Continued efforts should be made to promote influenza vaccina-
tion among groups at high risk of complications from influenza
infection, ensure national surge capacity for intensive care and
mechanical ventilation, secure antiviral stocks, guarantee their
availability and accessibility, and to provide guidelines to health
care providers on appropriate and timely use especially in
vulnerable populations.
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